• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance announces executive appointments

Covance announces executive appointments

May 4, 2012
CenterWatch Staff

Covance, a Princeton, N.J.-based provider of drug development services, has promoted Bill Klitgaard to corporate senior vice president and chief information officer, and Alison Cornell to corporate vice president and chief financial officer, effective May 8 upon approval by the board of directors.

Klitgaard has served Covance for 15 years, 12 of which as CFO—his most recent position. Informatics, an area of innovation for Covance that currently reports to Klitgaard, will be folded into the newly-expanded role of CIO.  As an executive sponsor of Covance's IT steering committee, Klitgaard played a critical leadership role in the development and funding of the company's major IT investments. Under his leadership, Covance implemented a complex, enterprise-wide finance system on time and on budget.  

Cornell joined Covance in 2004 from AT&T, where she served as financial vice president, forecasting, performance and investment analysis, heading finance for a $30 billion division. She was a key member of Covance’s clinical development leadership team from 2004 through 2010, serving as its finance leader, and played a critical role in transforming that business into a major growth driver for the company. She has been a driving force in the evaluation and lowering of our company's cost structure, and successfully designed and executed programs which have significantly lowered Covance’s DSOs. Most recently, Cornell served Covance as vice president of global financial planning and analysis, where she oversaw approximately 75% of the company's finance staff. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing